You are here

  • Home
  • Archive
  • Volume 19, Issue 5
  • Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer: A Sankai Gynecology Cancer Study Group Study

Article Text

Article menu
Download PDFPDF
Ovarian Cancer
Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer: A Sankai Gynecology Cancer Study Group Study
  1. Keiichi Fujiwara, MD, PhD*,
  2. Shoji Nagao, MD, PhD*,
  3. Junzo Kigawa, MD, PhD†,
  4. Jun Noma, MD, PhD‡,
  5. Nobuo Akamatsu, MD, PhD§,
  6. Yasunari Miyagi, MD, PhD∥,
  7. Fumitaka Numa, MD, PhD,
  8. Makoto Okada, MD, PhD** and
  9. Eriko Aotani, RN, MSN††
  1. *Department of Gynecologic Oncology, Saitama Medical University, International Medical Center, Hidaka, Saitama, Japan;
  2. †Tottori University, Koyama-Minami, Tottori, Japan;
  3. ‡Hiroshima City Hospital;
  4. §Himeji Red Cross Hospital, Tatsunomachi, Himejishi, Japan;
  5. ∥Okayama Ofuku Clinic,
  6. Tokuyama Central Hospital, Tokuyama, Japan;
  7. **Yamaguchi Red Cross Hospital, Yahatababa, Yamaguchi-shi, Yamaguchi, Japan;
  8. ††Kitasato University, Minato, Tokyo, Japan.
  1. Address correspondence and reprint requests to Keiichi Fujiwara, MD, PhD, Department of Gynecologic Oncology, Saitama Medical University, International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298 Japan. E-mail: fujiwara{at}saitama-med.ac.jp.

Abstract

Purpose: To assess the antitumor efficacy and safety of 2 treatment modalities: intraperitoneal carboplatin combined with intravenous (IV) paclitaxel.

Patients and Methods: Eligible patients were those with epithelial ovarian carcinoma or primary peritoneal carcinoma stages II to IV who underwent initial surgery and had a residual tumor size of 2 cm or larger. Patients received IV paclitaxel 175 mg/m2 followed by intraperitoneal carboplatin AUC6. The primary end point was a response. Secondary end points were toxicity, progression-free survival, and overall survival.

Results: Twenty-six patients were enrolled, and 24 patients were eligible for assessment. The response rate was 83.3% (95% CI, 62.6%-95.3%; Table 4). The median progression-free survival was 25 months. The median overall survival had not been reached. Incidences of grade (G) 3/4 hematological toxicities were absolute neutrophil count, 96%; hemoglobin, 29%; and thrombocytopenia, 16%. Nonhematological toxicities included G2 liver function, 4%; G3 sensory neuropathy, 8%; and G3 myalgia and arthralgia, 4%.

Conclusions: Intraperitoneal administration of carboplatin combined with IV paclitaxel was well tolerated and showed satisfactory response in the patients with bulky residual tumor. Large-scale phase III trial comparing with IV carboplatin is warranted in this patient population.

  • Intraperitoneal chemotherapy
  • Carboplatin
  • Ovarian cancer
  • Suboptimal residual disease
  • Phase II study

http://dx.doi.org/10.1111/IGC.0b013e3181a29dfe

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Conflict of Interest Statement: The authors declare that there are no conflicts of interest.